Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform

• Ngā kaituhi matua: Louise Conilh (Author), Guy Fournet (Author), Eric Fourmaux (Author), Angélique Murcia (Author), Eva-Laure Matera (Author), Benoît Joseph (Author), Charles Dumontet (Author), Warren Viricel (Author)
• Hōputu: Pukapuka
• I whakaputaina: MDPI AG, 2021-03-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

We herein report the development and evaluation of a novel HER2-targeting antibody-drug conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our hydrophilic monodisperse polysarcosine (PSAR) drug-linker platform (PSARlink). In vitro and in vivo experiments were conducted in...